Compare Iron Mountain Inc (IRM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Iron Mountain Inc trades at $124.2 (market cap $36.44B), while State Street SPDR S&P Biotech ETF trades at $159.64. The key difference: Iron Mountain Inc pays a 2.82% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Iron Mountain Inc nearer its low. Which is the better fit depends on your goals.
| IRM | XBI | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $133.06 | $164.28 |
52-Week Low | $78.86 | $86.92 |
Enterprise Value | $55.85B | — |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $121.56, up 0.34% today, with strong earnings beats in recent quarters and a bullish analyst consensus price target of $141.50. The stock shows bearish technical signals but benefits from robust revenue growth, particularly in data centers and digital solutions, though high debt levels and declining profit margins pose challenges. Recent news highlights CEO stock sales and institutional buying activity.
Outlook: IRM offers growth potential from data center expansion and recurring revenue streams, supported by positive analyst ratings. Key risks include elevated debt, margin pressure, and competitive threats. Investors should weigh strong operational performance against financial leverage and market sentiment shifts for balanced decision-making.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
